BACKGROUND: The clinical impact of PlA2 polymorphism has been investigated in several diseases, but the definition of its specific role on thrombotic cardiovascular complications has been challenging. We aimed to explore the effect of PlA2 polymorphism on outcome in patients with atherosclerosis. METHODS: We studied 400 consecutive patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention. A replication study was conducted in 74 hypertensive patients with cerebrovascular events while a group of 100 healthy subjects was included as control population. PlA genotype was determined by PCR-RFLP on genomic DNA from peripheral blood cells. Major adverse cardiac events (MACE), were considered as end points, and recorded at a mean follow up of 24 ± 4.3 months. RESULTS: The frequencies of PlA2 polymorphism was similar between groups and genotype distribution was in Hardy-Weinberg equilibrium. In patients with CAD, the presence of PlA2 allele was associated with higher incidence of cardiac death (13.1% vs. 1.5%, p = 0.0001), myocardial infarction (10.7% vs. 2.6%, p = 0.004) and needs of new revascularization (34.8% vs. 17.7%, p = 0.010). Accordingly, the Kaplan-Meier analysis for event free survival in patients harboring the PlA2 allele showed worse long-term outcome for these patients (p = 0.015). Cox regression analysis identified the presence of PlA2 as an independent predictor of cardiac death (OR: 9.594, 95% CI: 2.6 to 35.3, p = 0.002) and overall MACE (OR: 1.829, 95% CI: 1.054 to 3.176, p = 0.032). In the replication study, the PlA2 polymorphism increased the risk of stroke (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over TIA and was identified as an independent risk factor for stroke (B:-1.39; Wald: 7.15; p = 0.001). CONCLUSIONS: Our study demonstrates that in patients with severe atherosclerosis the presence of PlA2 allele is associated with thrombotic cardiovascular complications.
BACKGROUND: The clinical impact of PlA2 polymorphism has been investigated in several diseases, but the definition of its specific role on thrombotic cardiovascular complications has been challenging. We aimed to explore the effect of PlA2 polymorphism on outcome in patients with atherosclerosis. METHODS: We studied 400 consecutive patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention. A replication study was conducted in 74 hypertensivepatients with cerebrovascular events while a group of 100 healthy subjects was included as control population. PlA genotype was determined by PCR-RFLP on genomic DNA from peripheral blood cells. Major adverse cardiac events (MACE), were considered as end points, and recorded at a mean follow up of 24 ± 4.3 months. RESULTS: The frequencies of PlA2 polymorphism was similar between groups and genotype distribution was in Hardy-Weinberg equilibrium. In patients with CAD, the presence of PlA2 allele was associated with higher incidence of cardiac death (13.1% vs. 1.5%, p = 0.0001), myocardial infarction (10.7% vs. 2.6%, p = 0.004) and needs of new revascularization (34.8% vs. 17.7%, p = 0.010). Accordingly, the Kaplan-Meier analysis for event free survival in patients harboring the PlA2 allele showed worse long-term outcome for these patients (p = 0.015). Cox regression analysis identified the presence of PlA2 as an independent predictor of cardiac death (OR: 9.594, 95% CI: 2.6 to 35.3, p = 0.002) and overall MACE (OR: 1.829, 95% CI: 1.054 to 3.176, p = 0.032). In the replication study, the PlA2 polymorphism increased the risk of stroke (OR: 4.1, 95% CI: 1.63-12.4, p = 0.02) over TIA and was identified as an independent risk factor for stroke (B:-1.39; Wald: 7.15; p = 0.001). CONCLUSIONS: Our study demonstrates that in patients with severe atherosclerosis the presence of PlA2 allele is associated with thrombotic cardiovascular complications.
Authors: S C Smith; J T Dove; A K Jacobs; J W Kennedy; D Kereiakes; M J Kern; R E Kuntz; J J Popma; H V Schaff; D O Williams; R J Gibbons; J P Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith Journal: Circulation Date: 2001-06-19 Impact factor: 29.690
Authors: A D Michelson; M I Furman; P Goldschmidt-Clermont; M A Mascelli; C Hendrix; L Coleman; J Hamlington; M R Barnard; T Kickler; D J Christie; S Kundu; P F Bray Journal: Circulation Date: 2000-03-07 Impact factor: 29.690
Authors: J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook Journal: Circulation Date: 1987-07 Impact factor: 29.690
Authors: Stig E Bojesen; Klaus Juul; Peter Schnohr; Anne Tybjaerg-Hansen; Børge G Nordestgaard Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Teresa Strisciuglio; Giuseppe Di Gioia; Chiara De Biase; Massimiliano Esposito; Danilo Franco; Bruno Trimarco; Emanuele Barbato Journal: High Blood Press Cardiovasc Prev Date: 2015-05-19
Authors: Marion Flechtner-Mors; Samuel N George; Suemeyra Oeztuerk; Mark M Haenle; Wolfgang Koenig; Armin Imhof; Bernhard O Boehm; Tilmann Graeter; Richard A Mason; Wolfgang Kratzer; Atilla S Akinli Journal: BMC Res Notes Date: 2014-04-03
Authors: Bernd Stratmann; Tao Xu; Christa Meisinger; Barbara Menart; Michael Roden; Christian Herder; Harald Grallert; Annette Peters; Wolfgang Koenig; Thomas Illig; Heinz-Erich Wichmann; Rui Wang-Sattler; Wolfgang Rathmann; Diethelm Tschoepe Journal: Cardiovasc Diabetol Date: 2014-05-05 Impact factor: 9.951
Authors: Piotr Jankowski; Andrzej Pajak; Radoslaw Lysek; Anna Lukaszewska; Renata Wolfshaut-Wolak; Piotr Bogacki; Janusz Grodecki; Ewa Mirek-Bryniarska; Jadwiga Nessler; Piotr Podolec; Kalina Kawecka-Jaszcz; Danuta Czarnecka Journal: Medicine (Baltimore) Date: 2015-08 Impact factor: 1.817